Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
August 12 2020 - 4:01PM
Scipher Medicine and Galapagos sign collaboration in inflammatory
bowel disease
-- Companies to jointly validate novel drug
targets ---- Scipher eligible for upfront, opt-in
and milestone payments ---- Galapagos to progress
selected targets into drug discovery --
Mechelen, Belgium and Boston, USA; 12
August 2020 - Galapagos NV (Euronext & Nasdaq: GLPG) and
Scipher Medicine (Scipher), a Boston based privately held precision
medicine company focused on autoimmune diseases, today announce a
collaboration to advance novel drug targets identified by Scipher
for the treatment of inflammatory bowel disease (IBD).
Scipher combines its proprietary Network Medicine
Platform with molecular patient data and AI-based methods to
identify novel targets and pathways in autoimmune diseases,
including IBD.
Scipher and Galapagos will jointly validate a
suite of novel IBD targets discovered by Scipher after which
Galapagos has the exclusive option to progress up to five targets
into further drug discovery and development. Under the terms of the
agreement, Scipher is eligible to receive upfront, opt-in and
milestone payments and Galapagos will retain the rights for the
discovery, development and commercialization of therapeutics for
the selected target(s).
“Our breakthrough approach combines extensive
patient-level molecular data with AI methods to discover novel
targets with the potential to treat specific groups of patients,
including those not responding to therapies currently available,”
said Alif Saleh, Chief Executive Officer of Scipher Medicine. “This
partnership with Galapagos is a recognition of our innovative
approach to discover and validate novel targets that could offer a
solution for IBD patients.”
“The collaboration with Scipher is aligned with
our strategy to discover and develop novel modes of action
medicines with the potential to disrupt current treatment paradigms
to address high unmet needs in inflammatory diseases,” said Piet
Wigerinck, Chief Scientific Officer of Galapagos. “We believe that
our drug discovery and development expertise alongside Scipher’s
platform will support us in the discovery of exciting new drug
candidates.”
About Scipher MedicineScipher
Medicine, a precision immunology company, holds the fundamental
belief that patients deserve simple answers to treatment options
based on scientifically backed data. Leveraging our proprietary
Network Medicine platform and artificial intelligence, we
commercialize blood tests identifying a patient’s unique molecular
disease signature and match such signature to most effective
therapy ensuring patients receive optimal treatment from day one.
The unprecedented amount of patient molecular data generated from
our tests further drives development of novel and more effective
therapeutics. We partner with payers, providers and pharma along
the health care value chain to bring precision medicine to
autoimmune diseases.
Scipher Medicine is backed by Khosla Ventures,
Northpond Ventures and UnitedHealth Group. Visit
www.sciphermedicine.com and follow Scipher on Twitter, Facebook and
LinkedIn.
About Galapagos Galapagos NV discovers and
develops small molecule medicines with novel modes of action, three
of which show promising patient results and are currently in
late-stage development in multiple diseases. Our pipeline comprises
discovery through Phase 3 programs in inflammation, fibrosis,
osteoarthritis and other indications. Our ambition is to become a
leading global biopharmaceutical company focused on the discovery,
development and commercialization of innovative medicines. More
information at www.glpg.com.
Galapagos Forward-Looking Statement
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks,
uncertainties and other factors that could cause actual results to
differ materially from those referred to in the forward-looking
statements and, therefore, the reader should not place undue
reliance on them. These risks, uncertainties and other factors
include, without limitation, the inherent uncertainties associated
with target discovery and validation and drug discovery and
development activities (including that data from the ongoing
discovery activities may not support the validation of any novel
IBD targets or the development of any IBD drug candidates with
novel modes of action), expectations regarding the collaboration
with Scipher, that Galapagos may decide not to exercise any option
granted to it under the agreement with Scipher, and that Galapagos’
expectations regarding the further development of any potential
future in-licensed program, including its potential to address a
large unmet need in inflammatory diseases, may be incorrect, as
well as those risks and uncertainties identified in our Annual
Report on Form 20-F for the year ended December 31, 2019 and our
subsequent filings with the SEC. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. The forward-looking statements
contained herein are based on management’s current expectations and
beliefs and speak only as of the date hereof, and Galapagos makes
no commitment to update or publicly release any revisions to
forward-looking statements in order to reflect new information or
subsequent events, circumstances or changes in expectations.
###
Galapagos Contacts:
Investors:Elizabeth GoodwinVP Investor Relations
+1 781 460 1784
Sofie Van GijselSenior Director Investor Relations+32 485 19 14
15ir@glpg.com
Media:Carmen VroonenHead of Internal &
External Communications & Public Affairs+32 473 824 874
Anna GibbinsSenior Director Communications - Therapeutic
Areas+44 7717 801900communications@glpg.com
Media contacts Scipher Medicine:Cassidy McClain
Cassidy@canalecomm.com+1 619.849.6009
Brian McEvillybrian.mcevilly@sciphermedicine.com+1
858.736.5517
- Scipher Medicine and Galapagos sign collaboration in
inflammatory bowel disease
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024